{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:24:22Z","timestamp":1788909862939,"version":"build-2803163510"},"reference-count":167,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807091159001"],"award-info":[{"award-number":["JCYJ20230807091159001"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20250604122924032"],"award-info":[{"award-number":["JCYJ20250604122924032"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20320"],"award-info":[{"award-number":["U22A20320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125028"],"award-info":[{"award-number":["82125028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25A20125"],"award-info":[{"award-number":["U25A20125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373801"],"award-info":[{"award-number":["82373801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.apsb.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:04:54Z","timestamp":1779145494000},"page":"4854-4875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A destination-driven framework for nanoparticle-enabled targeted protein degradation"],"prefix":"10.1016","volume":"16","author":[{"given":"Yazhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5355-7238","authenticated-orcid":false,"given":"Huile","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.05.009_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109001","article-title":"Alpha-1 antitrypsin in autoimmune diseases: roles and therapeutic prospects","volume":"110","author":"Sun","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2026.05.009_bib2","article-title":"Applications of matrix metalloproteinase-9-related nanomedicines in tumors and vascular diseases","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2026.05.009_bib3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.drudis.2021.01.007","article-title":"Human ClpP protease, a promising therapy target for diseases of mitochondrial dysfunction","volume":"26","author":"Luo","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.05.009_bib4","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.drudis.2021.05.014","article-title":"Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection","volume":"26","author":"Ju","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.05.009_bib5","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1111\/bph.15844","article-title":"Targeting mitochondrial proteases for therapy of acute myeloid leukaemia","volume":"179","author":"Xiang","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.009_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.05.009_bib7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/D3MD00655G","article-title":"Progress in small-molecule inhibitors targeting PD-L1","volume":"15","author":"Xu","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2026.05.009_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.941522","article-title":"Discovering monoacylglycerol lipase inhibitors by a combination of fluorogenic substrate assay and activity-based protein profiling","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103508","article-title":"Targeting caseinolytic protease P and its AAA1 chaperone for tuberculosis treatment","volume":"28","author":"Xu","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.05.009_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/13543776.2025.2483399","article-title":"An updated patent review of EZH2 inhibitors (2024\u2013present)","volume":"35","author":"Wan","year":"2025","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.apsb.2026.05.009_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.05.009_bib13","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Challenges and opportunities in cancer drug resistance","volume":"121","author":"Ward","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2026.05.009_bib14","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/s41467-024-48006-9","article-title":"Evolution of triclosan resistance modulates bacterial permissiveness to multidrug resistance plasmids and phages","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.05.009_bib16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.05.009_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2026.05.009_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106159","article-title":"Focus on the classical and non-classical functions of EZH2: guide the development of inhibitors and degraders","volume":"178","author":"Zhang","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2026.05.009_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.05.009_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.05.009_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/acschembio.4c00799","article-title":"Discovery of DCAF16 binders for targeted protein degradation","volume":"20","author":"Campos","year":"2025","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib23","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.05.009_bib24","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2026.05.009_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib28","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy\u2013lysosome system","volume":"13","author":"Ji","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: a potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.apsb.2026.05.009_bib31","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1080\/15548627.2021.1967616","article-title":"Targeting lipid droplets for autophagic degradation by ATTEC","volume":"17","author":"Fu","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.apsb.2026.05.009_bib32","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.scib.2023.10.021","article-title":"Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects","volume":"68","author":"Tan","year":"2023","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.apsb.2026.05.009_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1225951","article-title":"Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future","volume":"14","author":"Yao","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.009_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.05.009_bib35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/pharmaceutics17081037","article-title":"Recent advances in nanomedicine: cutting-edge research on nano-PROTAC delivery systems for cancer therapy","volume":"17","author":"Wu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2026.05.009_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.tibs.2019.01.007","article-title":"Core Group Members of P. PROTEOSTASIS: a european network to break barriers and integrate science on protein homeostasis","volume":"44","author":"Dissmeyer","year":"2019","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.apsb.2026.05.009_bib37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-020-2402-x","article-title":"The proteome landscape of the kingdoms of life","volume":"582","author":"Muller","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-025-02439-w","article-title":"Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations","volume":"10","author":"Kuzu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.05.009_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","article-title":"Proteasomal and autophagic degradation systems","volume":"86","author":"Dikic","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2026.05.009_bib40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin\u2013proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.009_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.molcel.2016.09.014","article-title":"The k48\u2013k63 branched ubiquitin chain regulates NF-kappaB signaling","volume":"64","author":"Ohtake","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm2217","article-title":"Lysosomes: fusion and function","volume":"8","author":"Luzio","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","article-title":"Mechanisms of endocytosis","volume":"78","author":"Doherty","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2026.05.009_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1139\/bcb-2018-0008","article-title":"Phagocytosis: what's on the menu?","volume":"97","author":"Lancaster","year":"2019","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib46","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.009_bib47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s10637-025-01541-8","article-title":"Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia","volume":"43","author":"Wang","year":"2025","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2026.05.009_bib48","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1016\/j.apsb.2021.11.020","article-title":"Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma","volume":"12","author":"Xue","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.009_bib49","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization","volume":"12","author":"Yang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.009_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.931772","article-title":"The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants","volume":"13","author":"Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.009_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1351792","article-title":"Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice","volume":"15","author":"Yao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.05.009_bib52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41421-024-00711-x","article-title":"PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.apsb.2026.05.009_bib53","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.05.009_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100053","article-title":"Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases","volume":"77","author":"Fu","year":"2025","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2026.05.009_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor alpha for degradation with PROTACs: a promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.05.009_bib57","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin\u2013cyclosporin A and FKBP\u2013FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0092-8674(95)90439-5","article-title":"X-Ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12\u2013FK506 complex","volume":"82","author":"Griffith","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib59","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/378641a0","article-title":"Crystal structures of human calcineurin and the human FKBP12\u2013FK506\u2013calcineurin complex","volume":"378","author":"Kissinger","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ddtec.2019.02.004","article-title":"Cereblon modulators: low molecular weight inducers of protein degradation","volume":"31","author":"Chamberlain","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.apsb.2026.05.009_bib61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s42004-024-01125-2","article-title":"Bumped pomalidomide-based PROTACs","volume":"7","author":"Guo","year":"2024","journal-title":"Commun Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.009_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2019.10.005","article-title":"Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a mulfonamide molecular glue E7820","volume":"27","author":"Du","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2026.05.009_bib65","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: a cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153514","article-title":"Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells","volume":"132","author":"Sellar","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.05.009_bib67","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1021\/acs.jmedchem.4c01787","article-title":"Design and discovery of preclinical candidate LYG-409 as a highly potent and selective GSPT1 molecular glue degraders","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib68","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41589-024-01668-4","article-title":"Template-assisted covalent modification underlies activity of covalent molecular glues","volume":"20","author":"Li","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202508427","article-title":"Rational design of CDK12\/13 and BRD4 molecular glue degraders","volume":"64","author":"Zhuang","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.05.009_bib70","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2025.02.002","article-title":"VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation","volume":"32","author":"Mangano","year":"2025","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib72","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1021\/acs.jmedchem.5c00485","article-title":"ByeTAC: bypassing E-ligase-targeting chimeras for direct proteasome degradation","volume":"68","author":"Loy","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202501857","article-title":"Membrane-bounded intracellular E3 ubiquitin ligase-targeting chimeras (MembTACs) for targeted membrane protein degradation","volume":"64","author":"Mo","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.05.009_bib74","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/acs.jmedchem.2c01712","article-title":"Application of novel degraders employing autophagy for expediting medicinal research","volume":"66","author":"Li","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib75","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1021\/acs.biochem.1c00330","article-title":"Redefining the scope of targeted protein degradation: translational opportunities in hijacking the autophagy\u2013lysosome pathway","volume":"62","author":"Cassidy","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2026.05.009_bib76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nchembio.2007.33","article-title":"Protein S-guanylation by the biological signal 8-nitroguanosine 3\u2032,5\u2032-cyclic monophosphate","volume":"3","author":"Sawa","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib77","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.molcel.2013.10.024","article-title":"Endogenous nitrated nucleotide is a key mediator of autophagy and innate defense against bacteria","volume":"52","author":"Ito","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib78","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","article-title":"Targeting selective autophagy by AUTAC degraders","volume":"16","author":"Takahashi","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.apsb.2026.05.009_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.devcel.2017.02.016","article-title":"Cleaning house: selective autophagy of organelles","volume":"41","author":"Anding","year":"2017","journal-title":"Dev Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46657-z","article-title":"LC3-positive structures are prominent in autophagy-deficient cells","volume":"9","author":"Runwal","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.05.009_bib81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.048","article-title":"Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome","volume":"184","author":"Bourdenx","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib83","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/dna.1995.14.863","article-title":"The family of LAMP-2 proteins arises by alternative splicing from a single gene: characterization of the avian LAMP-2 gene and identification of mammalian homologs of LAMP-2b and LAMP-2c","volume":"14","author":"Gough","year":"1995","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nn.3637","article-title":"Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation","volume":"17","author":"Fan","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2026.05.009_bib85","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nbt.1608","article-title":"Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein","volume":"28","author":"Bauer","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-024-01364-y","article-title":"Targeted degradation of membrane and extracellular proteins with LYTACs","volume":"46","author":"Li","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2026.05.009_bib87","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib88","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","volume":"638","author":"Zhang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib89","doi-asserted-by":"crossref","first-page":"24272","DOI":"10.1021\/jacs.3c08886","article-title":"Insulin-like growth factor 2 (IGF2)-fused lysosomal targeting chimeras for degradation of extracellular and membrane proteins","volume":"145","author":"Zhang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib90","doi-asserted-by":"crossref","first-page":"17728","DOI":"10.1021\/jacs.4c02463","article-title":"Lysosome targeting chimeras for glut1-facilitated targeted protein degradation","volume":"146","author":"Luo","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib91","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41467-024-46130-0","article-title":"A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib92","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s41589-025-01924-1","article-title":"Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins","volume":"21","author":"Xiao","year":"2025","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202511467","article-title":"HerTACs enable tumor-selective lysosomal degradation of membrane and extracellular proteins via HER2 trafficking","volume":"64","author":"He","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.05.009_bib94","article-title":"Sortilin-mediated rapid, precise and sustained degradation of membrane proteins via mRNA-encoded lysosome-targeting chimera","volume":"12","author":"Chang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.05.009_bib95","doi-asserted-by":"crossref","first-page":"18705","DOI":"10.1021\/jacs.3c05109","article-title":"Targeted lysosomal degradation of secreted and cell surface proteins through the LRP-1 pathway","volume":"145","author":"Loppinet","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib96","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41587-025-02592-1","article-title":"Induced proximity at the cell surface","volume":"43","author":"Till","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib97","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","article-title":"Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins","volume":"17","author":"Gramespacher","year":"2022","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib98","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib99","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature11308","article-title":"Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of wnt receptors","volume":"488","author":"Koo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acssynbio.2c00587","article-title":"Receptor elimination by E3 ubiquitin ligase recruitment (REULR): a targeted protein degradation toolbox","volume":"12","author":"Siepe","year":"2023","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib101","article-title":"Highly specific cytokine receptor-targeting chimeras for targeted membrane protein degradation and sensitization of osimertinib in EGFR-mutated non-small-cell lung cancer","volume":"37","author":"Wu","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.05.009_bib102","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1021\/jacs.1c08521","article-title":"Covalently engineered nanobody chimeras for targeted membrane protein egradation","volume":"143","author":"Zhang","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib103","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1038\/s41467-025-62776-w","article-title":"Targeted degradation of cell surface proteins through endocytosis triggered by cell-penetrating peptide-small molecule conjugates","volume":"16","author":"He","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib104","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1021\/acscentsci.5c01647","article-title":"Molecularly built ligands degrade membrane receptors via enhancing their accumulation in lysosomes","volume":"11","author":"Zhang","year":"2025","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2026.05.009_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103387","article-title":"Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)","volume":"28","author":"Saraswat","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.05.009_bib106","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","article-title":"Fundamental aspects of DMPK optimization of targeted protein degraders","volume":"25","author":"Cantrill","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.05.009_bib107","doi-asserted-by":"crossref","first-page":"27862","DOI":"10.1021\/jacs.5c07041","article-title":"A covalent self-reporting peptide degrader enables real-time monitoring of targeted protein degradation in vivo","volume":"147","author":"Zhang","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib108","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1038\/s41467-024-50235-x","article-title":"Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins","volume":"15","author":"Chan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib109","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.009_bib110","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.31635\/ccschem.025.202506075","article-title":"Modification-powered engineering of the aptamer-based proteolysis targeting chimeras for enhanced membrane protein degradation","volume":"8","author":"Xu","year":"2026","journal-title":"CCS Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib111","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.apsb.2024.01.010","article-title":"Expanding the horizons of targeted protein degradation: a non-small molecule perspective","volume":"14","author":"Huang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.009_bib112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2533\/chimia.2022.341","article-title":"Linkers as game-changers in PROTAC technology: emphasizing general trends in PROTAC pharmacokinetics for their rational design","volume":"76","author":"Cecchini","year":"2022","journal-title":"Chimia"},{"key":"10.1016\/j.apsb.2026.05.009_bib113","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.05.009_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800213","article-title":"Chemical structure modifications and nano-technology applications for improving ADME-Tox properties, a review","volume":"352","author":"Farouk","year":"2019","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.apsb.2026.05.009_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.70013","article-title":"Rational proteolysis targeting chimera design driven by molecular modeling and machine learning","volume":"15","author":"Tan","year":"2025","journal-title":"WIREs Comput Mol Sci"},{"key":"10.1016\/j.apsb.2026.05.009_bib116","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s42256-022-00527-y","article-title":"Accelerated rational PROTAC design via deep learning and molecular simulations","volume":"4","author":"Zheng","year":"2022","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.apsb.2026.05.009_bib117","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/10717544.2021.1876182","article-title":"Stimuli-responsive drug delivery systems for head and neck cancer therapy","volume":"28","author":"Liang","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2026.05.009_bib118","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1039\/C9CS00575G","article-title":"Influence of nanomedicine mechanical properties on tumor targeting delivery","volume":"49","author":"Li","year":"2020","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2026.05.009_bib119","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.05.009_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.2020","article-title":"Nanotechnology-enabled targeted protein degradation for cancer therapeutics","volume":"16","author":"Zhao","year":"2024","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202207778","article-title":"Targeted protein degradation technology and nanomedicine: powerful allies against cancer","volume":"19","author":"Lin","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.apsb.2026.05.009_bib122","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.1021\/jacs.2c12824","article-title":"Targeted biomolecule regulation platform: a split-and-mix PROTAC approach","volume":"145","author":"Yang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib123","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.molcel.2023.11.027","article-title":"Multisite phosphorylation dictates selective E2\u2013E3 pairing as revealed by Ubc8\/UBE2H-GID\/CTLH assemblies","volume":"84","author":"Chrustowicz","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.05.009_bib124","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s44318-024-00047-y","article-title":"Structural insights into the ubiquitylation strategy of the oligomeric CRL2 E3 ubiquitin ligase","volume":"43","author":"Dai","year":"2024","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2026.05.009_bib125","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib126","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/pharmaceutics15082098","article-title":"Development of liposome systems for enhancing the PK properties of bivalent PROTACs","volume":"15","author":"Kou","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2026.05.009_bib127","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.05.009_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.143883","article-title":"Tailoring albumin-based theranostic PROTACs nanoparticles for enhanced NIR-II bioimaging and synergistic cancer chemo-phototherapy","volume":"469","author":"Hu","year":"2023","journal-title":"Chem Eng J"},{"key":"10.1016\/j.apsb.2026.05.009_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122038","article-title":"In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy","volume":"295","author":"Cho","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.05.009_bib130","article-title":"Chemotherapy-enabled colorectal cancer immunotherapy of self-delivery nano-PROTACs by inhibiting tumor glycolysis and avoiding adaptive immune resistance","volume":"11","author":"Zhao","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.05.009_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22241","article-title":"Targeted degradation of KRAS protein in non-small cell lung cancer: therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles","volume":"85","author":"Wang","year":"2024","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.apsb.2026.05.009_bib132","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib133","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.apsb.2026.05.009_bib134","article-title":"Nanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradation","author":"Ghosal","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2026.05.009_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202520235","article-title":"Ionizable nano-PROTAC overcomes endosomal entrapment for enhanced LRG1 degradation and tumor suppression","volume":"65","author":"Min","year":"2026","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.05.009_bib136","article-title":"Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.05.009_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113719","article-title":"Advancements in delivery systems for proteolysis-targeting chimeras (PROTACs): overcoming challenges and expanding biomedical applications","volume":"382","author":"Yu","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.05.009_bib138","doi-asserted-by":"crossref","first-page":"10458","DOI":"10.1021\/acs.jmedchem.3c00587","article-title":"Near-infrared-activatable PROTAC nanocages for controllable target protein degradation and on-demand antitumor therapy","volume":"66","author":"He","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.05.009_bib139","article-title":"Dual-programmable semiconducting polymer nanoPROTACs for deep-tissue sonodynamic-ferroptosis activatable immunotherapy","volume":"20","author":"Wang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.apsb.2026.05.009_bib140","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","article-title":"Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles","volume":"330","author":"Chen","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.05.009_bib141","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/acsmacrolett.4c00789","article-title":"Autophagy-activating nanoautophagosome-tethering compounds for targeted protein degradation specifically in tumor cells","volume":"14","author":"Xu","year":"2025","journal-title":"ACS Macro Lett"},{"key":"10.1016\/j.apsb.2026.05.009_bib142","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41565-023-01562-5","article-title":"Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors","volume":"19","author":"Huang","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib143","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"Supramolecular artificial nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.05.009_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd9994","article-title":"Designed proteins assemble antibodies into modular nanocages","volume":"372","author":"Divine","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.05.009_bib145","doi-asserted-by":"crossref","first-page":"34669","DOI":"10.1021\/jacs.4c13022","article-title":"Sonodynamic nano-LYTACs reverse tumor immunosuppressive microenvironment for cancer immunotherapy","volume":"146","author":"Xu","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib146","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-025-01703-4","article-title":"Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs","volume":"18","author":"Mamun","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.05.009_bib147","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.05.009_bib148","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41586-024-07948-2","article-title":"Designed endocytosis-inducing proteins degrade targets and amplify signals","volume":"638","author":"Huang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.05.009_bib149","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41565-024-01801-3","article-title":"Targeted protein degradation via cellular trafficking of nanoparticles","volume":"20","author":"Liu","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2026.05.009_bib150","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1038\/s41467-024-51720-z","article-title":"A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles","volume":"15","author":"Yao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib151","article-title":"Lysosome-targeting protein degradation through endocytosis pathway triggered by polyvalent nano-chimera for AD therapy","volume":"37","author":"Wang","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.05.009_bib152","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrm2745","article-title":"Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function","volume":"10","author":"Saftig","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2026.05.009_bib153","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2026.05.009_bib154","doi-asserted-by":"crossref","first-page":"19107","DOI":"10.1021\/jacs.3c07687","article-title":"Harnessing the lysosomal sorting signals of the cation-mndependent mannose-6-phosphate receptor for targeted degradation of membrane proteins","volume":"145","author":"Yu","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.05.009_bib156","series-title":"Bioengineered ferritin-based LYTAC platform for tumor-targeted therapy","author":"Fan","year":"2024"},{"key":"10.1016\/j.apsb.2026.05.009_bib157","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1021\/acs.nanolett.5c00341","article-title":"Multivalent RGD peptide-mediated nanochimera for lysosomal degradation of PDL1 protein","volume":"25","author":"Song","year":"2025","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2026.05.009_bib158","article-title":"Cancer specific CAIX-targeting supramolecular lysosome-targeting chimeras (supra-LYTAC) for targeted protein degradation","volume":"12","author":"Kim","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.05.009_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202417942","article-title":"A bifunctional lysosome-targeting chimera nanoplatform for tumor-selective protein degradation and enhanced cancer immunotherapy","volume":"37","author":"Xing","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.05.009_bib160","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/jfb13040188","article-title":"Precise design strategies of nanotechnologies for controlled drug delivery","volume":"13","author":"Huang","year":"2022","journal-title":"J Funct Biomater"},{"key":"10.1016\/j.apsb.2026.05.009_bib161","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1021\/jacs.5c17801","article-title":"An engineered nanovesicles-based lysosome-targeting protein degradation platform (NV-TACs) for cancer immunotherapy","volume":"148","author":"Xiao","year":"2026","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.05.009_bib162","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s44321-025-00371-8","article-title":"Extracellular vesicle-based targeted protein degradation platform for multiple extracellular proteins","volume":"18","author":"Tong","year":"2026","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2026.05.009_bib163","article-title":"An overview of nanoparticle protein corona literature","volume":"19","author":"Hajipour","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.apsb.2026.05.009_bib164","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41467-023-35902-9","article-title":"Endosomal sorting results in a selective separation of the protein corona from nanoparticles","volume":"14","author":"Han","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.05.009_bib165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/pharmaceutics14020247","article-title":"The hitchhiker's guide to human therapeutic nanoparticle development","volume":"14","author":"Ramos","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2026.05.009_bib166","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1021\/acsnano.2c11904","article-title":"Insights into the structure of comirnaty covid-19 vaccine: a theory on soft, partially bilayer-covered nanoparticles with hydrogen bond-stabilized mRNA-lipid complexes","volume":"17","author":"Szebeni","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.05.009_bib167","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/nnm-2017-0338","article-title":"Are existing standard methods suitable for the evaluation of nanomedicines: some case studies","volume":"13","author":"Gioria","year":"2018","journal-title":"Nanomedicine (Lond)"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:33:20Z","timestamp":1786221200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526003023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":167,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2211383526003023"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.05.009","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A destination-driven framework for nanoparticle-enabled targeted protein degradation","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}